Clinical trials: Disorder, Mood
Major Depressive Disorder
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
This study will evaluate the efficacy of ALKS 5461 when administered daily for 4 weeks to adults with Major Depressive Disorder (MDD) and inadequate response to antidepressant therapy.
- Trial name
- NCT01500200
- Testing
- ALKS 5461
- Where
- 27 sites in United States
- Volunteers
- 142 people
- Sponsor
- Alkermes, Inc.
Depressive Disorder
Controlled-release Paroxetine in Major Depressive Disorder (Double-blind, Placebo-controlled Study)
This is a randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy of controlled-release (CR) formulation of paroxetine orally administered to patients with major depressive disorder (MDD) at a…
- Trial name
- NCT00866294
- Testing
- paroxetine IR 10mg tablet, paroxetine IR 20mg tablet, Paroxetine CR 12.5mg tablet
- Where
- 67 sites in Japan, South Korea
- Volunteers
- 416 people
- Sponsor
- GlaxoSmithKline
Bipolar Disorder, Schizo Affective Disorder
Brain Stimulation and Cognitive Training
People with serious mental illness often report difficulties with thinking skills like memory. These difficulties can make it harder to perform day-to-day activities.
- Conditions
- Bipolar Disorder, Schizo Affective Disorder, Schizophrenia
- Trial name
- NCT03338673
- Testing
- tDCS, BrainHQ
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Michigan
Depression, Dysthymic Disorder
Duloxetine Treatment in Elderly With Dysthymia
Dysthymic disorder (DD) denotes chronic depression with fewer symptoms than major depressive disorder (MDD), and it affects ~ 2-4 % of adults with a similar prevalence in the elderly.
- Trial name
- NCT01852383
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
Investigating the Effectiveness of Telepsychiatry for Treating Major Depression in a Chinese American Nursing Home
The current use of telepsychiatry, or psychiatric care using videoconferencing, is very limited. The present study investigates the use of this method with a depressed Chinese American population in a nursing home.
- Trial name
- NCT00505518
- Testing
- Psychotropic medication (at discretion of psychiatrist), Collaborative psychiatric and primary medical care
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Massachusetts General Hospital
Bipolar Disorder
Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders
The primary aim of this proposal is to conduct a preliminary controlled trial of valproate and risperidone in children ages 3-7 yr. with bipolar disorders.
- Trial name
- NCT00221403
- Testing
- Risperidone oral solution, Valproate Oral Solution
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Major Depressive Disorder
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the safety and efficacy of an 8-week double-masked treatment of tasimelteon or placebo in male and female subjects with Major Depressive Disorder.
- Trial name
- MAGELLAN (NCT01428661)
- Testing
- tasimelteon
- Where
- 40 sites in United States
- Volunteers
- 507 people
- Sponsor
- Vanda Pharmaceuticals
Postpartum Depression
Postpartum Wellness
The purpose of this study is to test whether a web-based (eHealth) exercise intervention for new moms at increased risk for postpartum depression increases physical activity and decreases postpartum depression symptoms.
- Trial name
- POW (NCT04414696)
- Testing
- Exercise intervention
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Kaiser Permanente
Depression, Postpartum
A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)
The purpose of this study is to determine if treatment with SAGE-217 reduces depressive symptoms in females with severe postpartum depression (PPD) as compared to placebo.
- Trial name
- NCT04442503
- Testing
- SAGE-217
- Where
- 82 sites in United States, Spain and 1 more
- Volunteers
- 200 people
- Sponsor
- Biogen
Metabolic Syndrome, Bipolar Depression
Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance
The study is an open-label 8-week adjunctive trial of pioglitazone for the acute relief of bipolar depression comorbid with metabolic syndrome/insulin resistance.
- Conditions
- Metabolic Syndrome, Bipolar Depression, Insulin Resistance
- Trial name
- NCT00835120
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University Hospitals Cleveland Medical Center
Alcohol Dependence
Treatment Strategy for Alcohol Use Disorders in Veterans With TBI
The purpose of this research study is to understand the effectiveness of valproate (a common mood stabilizer) to further reduce alcohol misuse when given in addition to attending an alcohol rehabilitation program as well as the…
- Trial name
- AUD (NCT01342549)
- Testing
- Valproate, Naltrexone
- Where
- 2 sites in United States
- Volunteers
- 62 people
- Sponsor
- VA Office of Research and Development
Depressive Disorder
Study In Patients With Depression Not Responding to Selective Serotonin Re-uptake Inhibitors
This study is designed to evaluate the efficacy and safety in depressive patients who did not respond sufficiently to selective serotonin re-uptake inhibitors (SSRI).
- Trial name
- NCT00296517
- Testing
- 323U66 (Bupropion Hydrochloride Sustained Release)
- Where
- 62 sites in Japan
- Volunteers
- 325 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
Effects of Psilocybin in Major Depressive Disorder
The proposed pilot study will assess whether people with major depressive disorder experience psychological and behavioral benefits and/or harms from psilocybin.
- Trial name
- NCT03181529
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Johns Hopkins University
Bipolar Disorder
Oral Uridine for Treatment of Bipolar Depression in Adolescents
The purpose of the study is to see if the investigational medication uridine reduces depression symptoms in adolescents with bipolar disorder. Uridine is a naturally occurring chemical that is made by the human liver.
- Trial name
- NCT00841269
- Testing
- Uridine
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- University of Utah
Major Depressive Disorder, Suicidal Ideation
Ketamine in the Treatment of Suicidal Depression
This study is designed to compare the effectiveness of two medications, Ketamine and Midazolam, for rapidly relieving suicidal thoughts in people suffering from depression.
- Trial name
- NCT01700829
- Testing
- Ketamine, Midazolam
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia, Schizoaffective Disorder
Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes
The primary goal of this study is to examine the triglyceride/high-density lipoprotein (TG/HDL) ratio and the ischemic EKG changes in patients with schizophrenia, schizoaffective disorder or bipolar disorder.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00288353
- Testing
- aripiprazole (Abilify), ziprasidone (Geodon)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Northwestern University
Depressive Disorder
Safety and Efficacy Study in Patients With Major Depressive Disorder
The purpose of this study is to test if GSK163090 can reduce the symptoms of depression. The safety and how well the body can handle the drug will also be investigated.
- Trial name
- NCT00896363
- Testing
- GSK163090 1 mg, GSK163090 3 mg
- Where
- 15 sites in Russia
- Volunteers
- 99 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
A Long-Term Safety Study of ALKS 5461
This is a 52-week open-label study to evaluate the safety and tolerability of ALKS 5461.
- Trial name
- NCT02141399
- Testing
- ALKS 5461
- Where
- 158 sites in United States, Australia and 6 more
- Volunteers
- 1,485 people
- Sponsor
- Alkermes, Inc.
Premenstrual Dysphoric Disorder
Evaluating the Effectiveness of Sertraline in Treating Women With Premenstrual Dysphoric Disorder
This study will evaluate the effectiveness of sertraline in reducing symptoms in women diagnosed with premenstrual dysphoric disorder.
- Trial name
- NCT00536198
- Testing
- Sertraline
- Where
- 3 sites in United States
- Volunteers
- 252 people
- Sponsor
- Yale University
Depressive Disorder, Major
A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder
The primary purpose of this study is to evaluate the efficacy of flexibly dosed esketamine nasal spray compared with quetiapine extended-release (XR), both in combination with a continuing selective serotonin reuptake…
- Trial name
- ESCAPE-TRD (NCT04338321)
- Testing
- Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg
- Where
- 171 sites in Argentina, Austria and 22 more
- Volunteers
- 676 people
- Sponsor
- Janssen-Cilag International NV
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.